Single Use Support awarded "Solution Provider of the Year 2022"

micheal-eder

Michael Eder

July 1, 2022

Table of contents

Show

Single Use Support bags another trophy for innovation and was awarded "Solution Provider of the Year 2022" by Onco Cell Therapy Summit USA 2022 in Boston, MA.

The judges honored Single Use Support's end-to-end process solutions for filling-draining, freezing-thawing, storage & shipping while protecting valuable drug substances in the area of cell and gene therapy. The Austrian process solution provider adapts its innovative end-to-end platform technologies to advance biopharma with the goal to always simplify, accelerate and improve the quality of fluid management operations.

The RoSS.FILL CGT was emphasized as innovative product to fulfill the emgering need in vector and cell therapy manufacturing. It is based on its flagship RoSS.FILL platform that has become industry standard with over 100 systems installed worldwide. The adaptation was to reconfigure that system for faster, more accurate filling. The resulting platform system for aseptic fluid management for small single-use bioprocess containers is cleverly configured to be scalable for larger throughputs of vector manufacturing and equally capable for high accuracy filling for cell therapy manufacturing. 

RoSS.PADL, as standardized homogenizing solution, was created for cell therapy manufacturing to ensure the temperature and cryopreservant dosing can be done as part of the filling process. This non-invasive massager is ideal to fulfill the needs of quick, high accuracy, temperature regulated filling.

micheal-eder

Michael Eder

Senior Marketing Manager

Michael Eder, MA, is Senior Marketing Manager at Single Use Support. He is expert in pharma and health communication with his 10+ years experience in pharma. After completing his master's degree in International Healthcare Management at MCI The Entrepreneurial school in Innsbruck, he has gained experience in the pharmaceutical field manufacturing and commercialization of OTC and RX drugs. Michael creates articles about Freeze Thaw applications and Platform solutions from Single Use Support and is the author of current news with Single Use Support worldwide. 

More from Michael Eder

News

Single Use Support honoured as one of the ‘Best Managed Companies’

Deloitte Austria and Raiffeisenlandesbank Niederösterreich-Wien have honoured outstandingly managed companies. Single Use Support was the only winner from Tyrol to be honoured with the title ‘Best Managed Company 2024’. 

micheal-eder

Michael Eder

September 30, 2024

News

Third consecutive Pharma Innovation Award for Single Use Support

RoSS.PADL, the homogenizing solution from Single Use Support, was awarded the 2024 Innovation Award by Pharma Manufacturing.

micheal-eder

Michael Eder

September 26, 2024

Read more about News

News

Ania W. Payne, PhD Appointed New Chief Strategy and Marketing Officer of Single Use Support

Single Use Support Announces Ania Payne as new Chief Strategy and Marketing Officer further Strengthening the Leadership Team

michael-muehlegger

Michael Mühlegger

April 17, 2025

News

Darren Verlenden new CEO of Single Use Support

Darren Verlenden is the new CEO of Single Use Support and will work alongside Managing Director Christian Praxmarer. Further additions to Single Use Support’s top management set the course for global expansion.

michael-muehlegger

Michael Mühlegger

December 16, 2024

News

Single Use Support honoured as one of the ‘Best Managed Companies’

Deloitte Austria and Raiffeisenlandesbank Niederösterreich-Wien have honoured outstandingly managed companies. Single Use Support was the only winner from Tyrol to be honoured with the title ‘Best Managed Company 2024’. 

micheal-eder

Michael Eder

September 30, 2024

News

Novo Holdings Acquires Majority Stake in Single Use Support

The Danish company Novo Holdings has acquired a 60% majority stake in the Austrian-based company Single Use Support, thereby strengthening the company's further growth on a global level.

michael-muehlegger

Michael Mühlegger

May 14, 2024